A Single-centre, retrospective study to evaluate lymphopenia and its association with objective response to PD-1 inhibitor therapy (nivolumab or pembrolizumab) in patients with solid tumors
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
Most Recent Events
- 06 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology